Beneficial effects of testosterone administration on symptoms of the lower urinary tract in men with late-onset hypogonadism: A pilot study

References

• Yassin A, Saad F, Hoesl C E, Traish A M, Hammadeh M, Shabsigh R. Alpha-adrenoceptors are a common denominator in the pathophysiology of erectile function and BPH/LUTS - implications for clinical practice. Andrologia 2006; 38(1)1–12
   PubMed Web of Science ®Google Scholar
• Abrams P. Benign prostatic hyperplasia. Poorly correlated with symptoms. BMJ 1993; 307(6897)201
   PubMedGoogle Scholar
• Griffiths C J, Harding C, Blake C, McIntosh S, Drinnan M J, Robson W A, Abrams P, Ramsden P D, Pickard R S. A nomogram to classify men with lower urinary tract symptoms using urine flow and noninvasive measurement of bladder pressure. J Urol 2005; 174(4Pt1)1323–1326, discussion:1326; author reply:1326
   PubMedGoogle Scholar
• Thomas A W, Abrams P. Lower urinary tract symptoms, benign prostatic obstruction and the overactive bladder. BJU Int 2000; 85(Suppl.3)57–68, discussion:70–51
   PubMedGoogle Scholar
• Welch G, Weinger K, Barry M J. Quality-of-life impact of lower urinary tract symptom severity: results from the Health Professionals Follow-up study. Urology 2002; 59(2)245–250
   PubMedGoogle Scholar
• Hutchison A, Farmer R, Verhamme K, Berges R, Navarrete R V. The efficacy of drugs for the treatment of LUTS/BPH, a study in 6 European countries. Eur Urol 2007; 51(1)207–215, discussion:215–206
   PubMed Web of Science ®Google Scholar
• Kaufman J M, Vermeulen A. The decline of androgen levels in elderly men and its clinical and therapeutic implications. Endocr Rev 2005; 26(6)833–876
   PubMed Web of Science ®Google Scholar
• Kapoor D, Malkin C J, Channer K S, Jones T H. Androgens, insulin resistance and vascular disease in men. Clin Endocrinol (Oxf) 2005; 63(3)239–250
   PubMed Web of Science ®Google Scholar
• Vanderschueren D, Vandenput L, Boonen S, Lindberg M K, Bouillon R, Ohlsson C. Androgens and bone. Endocr Rev 2004; 25(3)389–425
   PubMed Web of Science ®Google Scholar
• Yassin A A, Saad F. Erectile dysfunction, metabolic syndrome, hypogonadism are intertwined. J Urol 2007; 177: 288
   PubMedGoogle Scholar
• Rosen R C. Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opin Urol 2006; 16(1)11–19
   PubMed Web of Science ®Google Scholar
• McVary K. Lower urinary tract symptoms and sexual dysfunction: epidemiology and pathophysiology. BJU Int 2006; 97(Suppl.2)23–28, discussion:44-25
   PubMedGoogle Scholar
• Glina S, Santana A W, Azank F, Mello L F, Moreira E D, Jr. Lower urinary tract symptoms and erectile dysfunction are highly prevalent in ageing men. BJU Int 2006; 97(4)763–765
   PubMedGoogle Scholar
• Paick J S, Yang J H, Kim S W, Ku J H. Are age, anthropometry and components of metabolic syndrome-risk factors interrelated with lower urinary tract symptoms in patients with erectile dysfunction? A prospective study. Asian J Androl 2007; 9(2)213–220
   PubMedGoogle Scholar
• Kasturi S, Russell S, McVary K T. Metabolic syndrome and lower urinary tract symptoms secondary to benign prostatic hyperplasia. Curr Urol Rep 2006; 7(4)288–292
   PubMedGoogle Scholar
• Rohrmann S, Smit E, Giovannucci E, Platz E A. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes (Lond) 2005; 29(3)310–316
   PubMed Web of Science ®Google Scholar
• Nieschlag E. Testosterone treatment comes of age: new options for hypogonadal men. Clin Endocrinol (Oxf) 2006; 65(3)275–281
   PubMed Web of Science ®Google Scholar
• Daig I, Heinemann L A, Kim S, Leungwattanakij S, Badia X, Myon E, Moore C, Saad F, Potthoff P, Thai do M. The Aging Males’ Symptoms (AMS) scale: review of its methodological characteristics. Health Qual Life Outcomes 2003; 1(1)77
   PubMedGoogle Scholar
• Mskhalaya G, Rozhivanov R V, Nesterov M N, Kalinchenko S Y. The efficiency and safety of human chorionic gonadotropin (HCG) therapy on low urinary tract symptoms (LUTS) in men with benign prostatic hyperplasia (BPH). Paper presented at the Fifth Congress of The International Society for the Study of The Aging Male, SalzburgAustria, February, 2006
   Google Scholar
• Karazindiyanogˇlu S, Çayan S. Beneficial effects of testosterone administration of bladder function. Sixth Annual Meeting of the European Association of Urology, BerlinGermany, March, 2007
   Google Scholar
• Mskhalaya G, Tishova J A, Koval A N, Vishnevskiy E L, Kalinchenko S Y. The efficiency of testosterone undecanoate (Nebido) therapy on lower urinary tract symptoms (LUTS) in men with late-onset hypogonadism (LOH). First European Congress of the Society for the Study of the Aging Male, WarsawPoland, June, 2007, Abstract Book: 36
   Google Scholar
• Saad F, Gooren L J, Haider A, Yassin A. A dose-response study of testosterone on sexual dysfunction and features of the metabolic syndrome using testosterone gel and parenteral testosterone undecanoate. J Androl 2008; 29(1)102–105
   PubMedGoogle Scholar
• Seftel A, Rosen R, Kuritzky L. Physician perceptions of sexual dysfunction related to benign prostatic hyperplasia (BPH) symptoms and sexual side effects related to BPH medications. Int J Impot Res 2007; 19(4)386–392
   PubMed Web of Science ®Google Scholar
• Rosenzweig B A, Bolina P S, Birch L, Moran C, Marcovici I, Prins G S. Location and concentration of estrogen, progesterone, and androgen receptors in the bladder and urethra of the rabbit. Neurourol Urodyn 1995; 14(1)87–96
   PubMed Web of Science ®Google Scholar
• Keast J R. The autonomic nerve supply of male sex organs - an important target of circulating androgens. Behav Brain Res 1999; 105(1)81–92
   PubMedGoogle Scholar
• Watkins T W, Keast J R. Androgen-sensitive preganglionic neurons innervate the male rat pelvic ganglion. Neuroscience 1999; 93(3)1147–1157
   PubMed Web of Science ®Google Scholar
• Hall R, Andrews P L, Hoyle C H. Effects of testosterone on neuromuscular transmission in rat isolated urinary bladder. Eur J Pharmacol 2002; 449(3)301–309
   PubMed Web of Science ®Google Scholar
• Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Barbara Vannelli G, Carini M, Forti G, Maggi M. Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007; 148(3)1019–1029
   PubMed Web of Science ®Google Scholar
• Muto S, Yasuda M, Kamiyama Y, Ide H, Horie S. Testosterone decreased urinary frequency in nNOS-deficient mice. Int J Androl 2007; 31: 67–70
   PubMedGoogle Scholar
• McVary K T. Unexpected insights into pelvic function following phosphodiesterase manipulation - what's next for urology?. Eur Urol 2006; 50(6)1153–1156
   PubMedGoogle Scholar
• Bhasin S, Cunningham G R, Hayes F J, Matsumoto A M, Snyder P J, Swerdloff R S, Montori V M. Testosterone therapy in adult men with androgen deficiency syndromes: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2006; 91(6)1995–2010
   PubMed Web of Science ®Google Scholar